Fra-1 regulates its target genes via binding to remote enhancers without exerting major control on chromatin architecture in triple negative breast cancers.


Journal

Nucleic acids research
ISSN: 1362-4962
Titre abrégé: Nucleic Acids Res
Pays: England
ID NLM: 0411011

Informations de publication

Date de publication:
18 03 2021
Historique:
accepted: 25 01 2021
revised: 21 12 2020
received: 13 03 2020
pubmed: 4 2 2021
medline: 27 3 2021
entrez: 3 2 2021
Statut: ppublish

Résumé

The ubiquitous family of dimeric transcription factors AP-1 is made up of Fos and Jun family proteins. It has long been thought to operate principally at gene promoters and how it controls transcription is still ill-understood. The Fos family protein Fra-1 is overexpressed in triple negative breast cancers (TNBCs) where it contributes to tumor aggressiveness. To address its transcriptional actions in TNBCs, we combined transcriptomics, ChIP-seqs, machine learning and NG Capture-C. Additionally, we studied its Fos family kin Fra-2 also expressed in TNBCs, albeit much less. Consistently with their pleiotropic effects, Fra-1 and Fra-2 up- and downregulate individually, together or redundantly many genes associated with a wide range of biological processes. Target gene regulation is principally due to binding of Fra-1 and Fra-2 at regulatory elements located distantly from cognate promoters where Fra-1 modulates the recruitment of the transcriptional co-regulator p300/CBP and where differences in AP-1 variant motif recognition can underlie preferential Fra-1- or Fra-2 bindings. Our work also shows no major role for Fra-1 in chromatin architecture control at target gene loci, but suggests collaboration between Fra-1-bound and -unbound enhancers within chromatin hubs sometimes including promoters for other Fra-1-regulated genes. Our work impacts our view of AP-1.

Identifiants

pubmed: 33533919
pii: 6127268
doi: 10.1093/nar/gkab053
pmc: PMC7968996
doi:

Substances chimiques

Chromatin 0
FOSL2 protein, human 0
Fos-Related Antigen-2 0
Proto-Oncogene Proteins c-fos 0
Transcription Factor AP-1 0
fos-related antigen 1 0
p300-CBP Transcription Factors EC 2.3.1.48

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2488-2508

Subventions

Organisme : Medical Research Council
ID : MC_UU_00016/14
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12009/15
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N00969X/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106130/Z/14/Z
Pays : United Kingdom

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of Nucleic Acids Research.

Références

Oncogene. 2010 Aug 19;29(33):4732-40
pubmed: 20543861
Oncogene. 1997 Feb 20;14(7):837-47
pubmed: 9047391
Elife. 2019 Jul 11;8:
pubmed: 31294690
Nat Rev Cancer. 2010 Jan;10(1):65-76
pubmed: 20029425
Essays Biochem. 2019 Apr 23;63(1):157-165
pubmed: 30940740
Eur J Cancer. 2005 Nov;41(16):2449-61
pubmed: 16199154
Oncogene. 2012 Mar 22;31(12):1493-503
pubmed: 21822309
Nat Genet. 2007 Mar;39(3):311-8
pubmed: 17277777
Mol Cell Biol. 1999 Jan;19(1):330-41
pubmed: 9858557
Bioessays. 2018 Oct;40(10):e1800078
pubmed: 30144132
Mol Cell Biol. 2002 Jan;22(2):587-98
pubmed: 11756554
Nat Methods. 2016 Jan;13(1):74-80
pubmed: 26595209
Breast Cancer Res. 2018 Jan 30;20(1):9
pubmed: 29382358
BMC Cancer. 2007 Jan 25;7:17
pubmed: 17254320
Mol Cell Biol. 2008 Sep;28(18):5764-76
pubmed: 18644873
Genes Cells. 2003 Mar;8(3):263-73
pubmed: 12622723
Genome Res. 2015 Apr;25(4):504-13
pubmed: 25677180
Cell Death Differ. 2015 Feb;22(2):336-50
pubmed: 25301070
Mol Cell Biol. 2003 Jun;23(12):4401-15
pubmed: 12773579
Nature. 2014 Mar 27;507(7493):455-461
pubmed: 24670763
BMC Cancer. 2013 Sep 28;13:441
pubmed: 24073962
J Mol Biol. 1986 Apr 5;188(3):415-31
pubmed: 3525846
Mol Cell Biol. 1991 May;11(5):2451-9
pubmed: 1901942
Mol Cell. 2010 Apr 9;38(1):114-27
pubmed: 20385094
Cell Signal. 2007 Apr;19(4):695-704
pubmed: 17052890
Mol Cell Biol. 2004 Jun;24(11):4696-709
pubmed: 15143165
Nat Genet. 2020 Dec;52(12):1271-1281
pubmed: 33257899
Nucleic Acids Res. 2018 Sep 6;46(15):e91
pubmed: 29800273
Oncogene. 2020 Jun;39(23):4491-4506
pubmed: 32385348
Nat Commun. 2015 Apr 08;6:6782
pubmed: 25851810
Nucleic Acids Res. 2014;42(17):11011-24
pubmed: 25200076
Mol Cell Biol. 2015 Jan;35(1):88-100
pubmed: 25332240
Oncogene. 2015 Aug 20;34(34):4421-8
pubmed: 25381818
Nat Commun. 2018 Mar 5;9(1):943
pubmed: 29507293
Mol Cell Biol. 2003 Oct;23(19):7030-43
pubmed: 12972619
Mol Cell Biol. 2002 Jul;22(13):4952-64
pubmed: 12052899
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Rev Genet. 2020 May;21(5):292-310
pubmed: 31988385
J Biol Chem. 2011 Nov 25;286(47):40974-86
pubmed: 21937452
J Invest Dermatol. 2008 Mar;128(3):530-41
pubmed: 17882273
Nat Genet. 2019 Jan;51(1):128-137
pubmed: 30478436
Bioinformatics. 2016 Aug 15;32(16):2528-30
pubmed: 27153642
Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):11-23
pubmed: 31034924
Cancer Res. 2014 Jul 15;74(14):3983-94
pubmed: 24830720
J Cell Sci. 2004 Dec 1;117(Pt 25):5965-73
pubmed: 15564374
Nat Genet. 2018 Dec;50(12):1744-1751
pubmed: 30374068
Oncogene. 2005 Jan 27;24(5):801-9
pubmed: 15558021
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5139-44
pubmed: 23483055
Nature. 2014 Aug 7;512(7512):96-100
pubmed: 25043061
Cell Cycle. 2007 Nov 1;6(21):2633-9
pubmed: 17957143
Mol Cell. 2017 Sep 21;67(6):1037-1048.e6
pubmed: 28890333
Curr Opin Chem Biol. 2018 Aug;45:195-203
pubmed: 30025258
Nat Rev Cancer. 2003 Nov;3(11):859-68
pubmed: 14668816
PLoS Genet. 2012;8(6):e1002769
pubmed: 22737084
Transcription. 2013 Jan-Feb;4(1):18-23
pubmed: 23131664
Cell Signal. 2009 Jun;21(6):969-77
pubmed: 19249353
BMC Genomics. 2019 Feb 1;20(1):103
pubmed: 30709337
Nat Cell Biol. 2002 May;4(5):E131-6
pubmed: 11988758
Cancer Cell. 2013 Sep 9;24(3):347-64
pubmed: 24029232
Oncotarget. 2017 Mar 15;8(13):20572-20587
pubmed: 28411283
Mol Biol Rep. 2020 Jan;47(1):737-752
pubmed: 31612408
Brief Bioinform. 2020 May 21;21(3):836-850
pubmed: 30895290
Cancer Cell. 2006 Dec;10(6):515-27
pubmed: 17157791
Nat Commun. 2019 Nov 27;10(1):5412
pubmed: 31776347
EMBO J. 2003 Jul 15;22(14):3686-95
pubmed: 12853483
Oncogene. 2012 Nov 22;31(47):4889-97
pubmed: 22286759
Mol Cancer Res. 2019 Oct;17(10):1999-2014
pubmed: 31300541
Mol Cell Biol. 2007 Jun;27(11):3936-50
pubmed: 17371847
Nat Commun. 2019 Sep 25;10(1):4369
pubmed: 31554806
BMC Genomics. 2019 Jun 20;20(1):511
pubmed: 31221079
Nat Genet. 2018 Aug;50(8):1151-1160
pubmed: 29988121
Epigenomics. 2018 Apr 1;10(4):483-498
pubmed: 29583027
J Cell Sci. 2003 Dec 15;116(Pt 24):4957-63
pubmed: 14625389
Eur J Cancer. 2010 Jun;46(9):1650-60
pubmed: 20226654
Nat Cell Biol. 2002 Aug;4(8):556-64
pubmed: 12134156
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Mol Cell. 2020 Jan 16;77(2):324-337.e8
pubmed: 31704182
Oncogene. 2005 Feb 17;24(8):1434-44
pubmed: 15608675
Nat Rev Genet. 2020 Feb;21(2):71-87
pubmed: 31605096
Cancer Lett. 2017 Jan 28;385:97-107
pubmed: 27816489
J Biol Chem. 2016 Mar 25;291(13):6714-22
pubmed: 26851278
Nat Genet. 2017 Jul;49(7):1073-1081
pubmed: 28581502

Auteurs

Fabienne Bejjani (F)

IGMM, Univ Montpellier, CNRS, Montpellier, France.
PRASE, DSST, ER045, Lebanese University, Beirut, Lebanon.

Claire Tolza (C)

IGMM, Univ Montpellier, CNRS, Montpellier, France.

Mathias Boulanger (M)

IGMM, Univ Montpellier, CNRS, Montpellier, France.

Damien Downes (D)

Medical Research Council, Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, UK.

Raphaël Romero (R)

IMAG, Univ Montpellier, CNRS, Montpellier, France.
LIRMM, Univ Montpellier, CNRS, Montpellier, France.

Muhammad Ahmad Maqbool (MA)

IGMM, Univ Montpellier, CNRS, Montpellier, France.

Amal Zine El Aabidine (A)

IGMM, Univ Montpellier, CNRS, Montpellier, France.

Jean-Christophe Andrau (JC)

IGMM, Univ Montpellier, CNRS, Montpellier, France.

Sophie Lebre (S)

IMAG, Univ Montpellier, CNRS, Montpellier, France.

Laurent Brehelin (L)

LIRMM, Univ Montpellier, CNRS, Montpellier, France.

Hughes Parrinello (H)

Montpellier GenomiX, MGX, BioCampus Montpellier, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France.

Marine Rohmer (M)

Montpellier GenomiX, MGX, BioCampus Montpellier, CNRS, INSERM, Univ. Montpellier, F-34094 Montpellier, France.

Tony Kaoma (T)

Computational Biomedecine, Quantitative Biology Unit, Luxembourg Institute of Health, Strassen, Luxembourg.

Laurent Vallar (L)

Proteome and Genome Research Unit, Department of Oncology, Luxembourg Institute of Health, Luxembourg, Luxembourg.

Jim R Hughes (JR)

Medical Research Council, Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, UK.

Kazem Zibara (K)

PRASE, DSST, ER045, Lebanese University, Beirut, Lebanon.
Biology Department, Faculty of Sciences-I, Lebanese University, Beirut, Lebanon.

Charles-Henri Lecellier (CH)

IGMM, Univ Montpellier, CNRS, Montpellier, France.
LIRMM, Univ Montpellier, CNRS, Montpellier, France.

Marc Piechaczyk (M)

IGMM, Univ Montpellier, CNRS, Montpellier, France.

Isabelle Jariel-Encontre (I)

IGMM, Univ Montpellier, CNRS, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH